Table 5.

Sensitivity Analyses of Residual Lifetime Incidence of CKD in Adults Aged 30 to 49 Years

Analysis	CKD	Stage 3a+	Stage 3b+	Stage 4+	Stage 5
Baseline	54.61	47.30	24.26	9.24	3.14
eGFR slope +50%	80.90	79.39	61.32	34.92	13.34
eGFR slope −50%	27.11	11.48	2.98	0.98	0.38
Stages 3 and 4 mortality +10%	54.61	47.33	23.40	8.71	2.85
Stages 3 and 4 mortality −10%	54.59	47.28	24.99	9.88	3.46
Stage 5 mortality +25%	54.62	47.30	24.26	9.25	3.14
Stage 5 mortality −25%	54.61	47.31	24.26	9.25	3.14
Age-specific CKD mortality rates	54.61	47.29	23.91	9.00	3.25
Diabetes incidence +33%	55.20	47.65	25.42	10.50	3.66
Diabetes incidence −33%	53.99	46.95	22.89	7.99	2.58
Proteinuria incidence +15%	55.53	47.50	24.35	9.39	3.19
Proteinuria incidence −15%	53.59	47.19	24.04	9.08	3.04
Hypertension incidence +10%	54.65	47.31	24.23	9.23	3.09
Hypertension incidence −10%	54.62	47.38	24.10	9.34	3.19

Note: Values are given as percentage. Residual lifetime incidence for CKD shows the projected percentage of persons who do not currently have CKD who will develop CKD in their lifetime. Residual lifetime incidence for CKD stage 3a+ shows the projected percentage of persons with current eGFR ≥ 60 mL/min/1.73 m² who will develop eGFR < 60 mL/min/1.73 m² in their lifetime. Residual lifetime incidence for CKD stages 3b+, 4+, and 5 are defined in a similar manner, with eGFR cutoff points of 45, 30, and 15 mL/min/1.73 m², respectively.

Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.